DESCRIPTION

Glipotec-MV1 Tablet (Glimepiride 1 mg + Voglibose 0.2 mg + Metformin 500 mg (PR) is a combination of Glimepiride, Metformin and Voglibose. It is an anti-diabetic medicine used for the treatment of type 2 diabetes in adults. It works by increasing insulin release and improving your body's response to insulin (a hormone that enables your body to use sugar). It also prevents the breakdown of carbohydrates to glucose (sugar) and thereby lowers your blood sugar levels. 

INDICATION

• Type II Diabetes Mellitus : Type 2 Diabetes is a condition that causes an increase in blood sugar levels. In type 2 diabetes, the insulin produced by your body cannot be used properly by the cells to convert glucose into energy. Glipotec-MV1 Tablet (Glimepiride 1 mg + Voglibose 0.2 mg + Metformin 500 mg (PR) effectively reduces blood sugar levels in Type II Diabetes.

MECHANISM OF ACTION

Glimepiride  : Glimepiride is a sulfonylurea that stimulates the pancreas to release more insulin. It binds to specific receptors on pancreatic beta cells, which increases insulin secretion and lowers blood glucose levels.

Voglibose : Voglibose is an alpha-glucosidase inhibitor that works by inhibiting enzymes in the intestines responsible for breaking down carbohydrates. This slows down the digestion and absorption of carbohydrates, leading to reduced postprandial (after meal) blood glucose spikes.

Metformin  : Metformin is a biguanide that decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues. It works by reducing glucose production in the liver and increasing glucose uptake and utilization in the body's cells. Additionally, Metformin slightly reduces glucose absorption from the intestines.

DRUG INTERACTIONS

Drug-Drug Interaction: Glipotec-MV1 Tablet (Glimepiride 1 mg + Voglibose 0.2 mg + Metformin 500 mg (PR) may interact with insulin, high blood pressure-lowering pills (hydrochlorothiazide, amlodipine), water pills/diuretics (furosemide), heart failure-related medicines (digoxin), anti-hypertensive (metoprolol), steroids (prednisolone), thyroid hormones etc. So, tell your doctor if you are using these drugs before taking Glipotec-MV1 Tablet.

Drug-Food Interaction: Taking Glipotec-MV1 Tablet (Glimepiride 1 mg + Voglibose 0.2 mg + Metformin 500 mg (PR)with alcoholic beverages may increase the risk of a rare but serious and potentially life-threatening condition known as lactic acidosis (build-up of lactic acid in the blood) and hypoglycaemia.

Drug-Disease Interaction: Glipotec-MV1 Tablet (Glimepiride 1 mg + Voglibose 0.2 mg + Metformin 500 mg (PR) should be avoided in patients with vitamin B12 deficiency, kidney problems, liver problems, cardiovascular disease (heart-related issues) and low blood sugar level (hypoglycaemia) as it may worsen the condition.

SIDE EFFECTS OF GLIPOTEC-MV1 TABLET

Major & minor side effects for Glipotec-MV1 Tablet

• Hypoglycaemia (low blood glucose level) 
• Taste change
• Nausea
• Diarrhoea
• Stomach pain
• Flatulence
• Headache
• Upper respiratory symptoms

PRECAUTION

When using Glipotec-MV1 Tablet (Glimepiride 1 mg + Voglibose 0.2 mg + Metformin 500 mg (PR) monitor blood glucose levels to manage the risk of hypoglycemia from Glimepiride. Regularly assess renal function due to Metformin’s potential impact on the kidneys and risk of lactic acidosis. Be aware of gastrointestinal side effects from Voglibose and Metformin, such as bloating and diarrhea, and start at a lower dose if needed. Periodically check liver function due to potential effects from both Metformin and Voglibose. Inform your healthcare provider of all medications to avoid drug interactions, and attend regular follow-up appointments to evaluate treatment efficacy and adjust dosages as necessary.

DISCLAIMER

The information on this website is provided for general informational purposes only and is not medical advice.. It is not a substitute for professional medical advice, diagnosis, or treatment. Consult a qualified healthcare provider for personalized advice. We do not endorse any specific products, treatments, or services mentioned.